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Patients with atrial fibrillation (AF) are 5 times more likely to have a stroke than individuals in sinus rhythm, and 1 in every 5 strokes is secondary to AF. [1] [2] [3] Unfortunately, AFrelated thrombo-emboli are larger and result in ischemic strokes that are more devastating than those secondary to carotid artery disease or other etiologies. 4, 5 Lifelong oral anticoagulation with warfarin has been the guidelinebased therapy to reduce the risk of AF-related ischemic strokes in patients with a CHA 2 DS 2 -VASc (congestive heart failure, hypertension, age>75 and diabetes mellitus, previous history of stroke or transient ischemic attack, vascular disease, age 65-74 years, and female sex category) score 2. Anticoagulation (AC), however, inherently predisposes to bleeding, including hemorrhagic stokes. Moreover, a significant percentage of patients with AF have relative or absolute contraindications to AC. Even those who can take it do not necessarily experience maximum anticoagulant protection. Despite demonstrating warfarin's benefit in preventing approximately one-half of AF-related strokes, the target international normalized ratio (INR) is achieved in only approximately 60% of patients despite best practices in dosing and monitoring. 6, 7 A recent registry reported that among patients on warfarin for AF, only 26% were found to have a stable INR within therapeutic range. 8 The 4 major randomized controlled trials (RCTs) for nonvitamin K oral anticoagulants (NOACs) have shown the time in therapeutic range (TTR) in the warfarin-treated arms to range from 55% to 68% despite optimal dosing and INR monitoring. 9 In their meta-analysis of the 4 RCTs comparing NOACs with warfarin, Ruff et al 10 found NOACs to be superior to warfarin in reducing intracranial bleeding, but not bleeding elsewhere. Like warfarin, NOACs still subject the patient to an above-baseline predisposition to bleeding. They also both subject the patient to lifelong therapy, and despite NOACs eliminating the need for frequent blood tests, dabigatran and apixaban replace the daily warfarin dosing with a twice-daily dosing regimen. Finally, approximately 20% to 25% of patients on NOACs have discontinued the agent at 2 years of follow-up.
These shortcomings of anticoagulation triggered a search for alternatives. If thrombi are identified in the left heart of patients with nonvalvular AF-related strokes, they are in the left atrial appendage (LAA) 90% of the time. 11 This observation led to an increased interest in closing the LAA mechanically as a potential means of reducing the stroke rate in patients with nonvalvular AF. Successful LAA occlusion can potentially provide patients who cannot tolerate OAC therapy a means of stroke risk reduction, and to spare those who can receive OAC the potential hazards, inconveniences and costs of lifelong anticoagulation. In this review, we discuss techniques and devices aimed at LAA exclusion.
LAA OCCLUSION OR EXCISION
The first known attempt at occluding or excising the LAA to prevent stroke was reported in 1949 and the outcomes were dismal. 12 14 demonstrated a therapeutic benefit of LAA occlusion but also noted that an incomplete occlusion was detrimental because the residual was thrombogenic. In their retrospective report on patients undergoing mitral valve replacement, they found that leaving the LAA intact was an independent predictor of stroke with a 6.7-fold increased risk, whereas incomplete closure of the LAA increased the risk of stroke by 11.9-fold. Although the benefits of successfully closing the LAA could not always be reproduced by other investigators, the detrimental consequences of incomplete LAA closure were consistent. 15, 16 Because at that time only approximately 60% of the LAAs could be closed completely, 40% of the patients were left with a higher stroke risk than those with an intact LAA. 17, 18 The inability to attain complete LAA closure not only increased the stroke risk but it also precluded an accurate determination of the relationship between LAA occlusion and stroke reduction. However, in 2006, the American College of Cardiology and the American Heart Association (ACC/AHA) recommended exclusion of the LAA surgically during surgical ablation of AF or mitral valve surgery. 19 Nevertheless, controversy persisted regarding the potential value versus the potential harm of occluding the LAA for stroke in patients with nonvalvular AF. 20 Approximately 110 publications discussed the LAA over the 30 years from 1960 to 1990. Interestingly, more than 1000 publications exist discussing the LAA from 2000 to date. 21 Unfortunately, this exponential increased interest in the LAA was not translated into well-powered RCTs except recently. The literature is abundant in singleinstitution pilot studies and case series, but only 1 adequately powered RCT was completed. In 2014, results from the intermediate to late follow-up of this RCT have, for the first time, provided objective evidence for LAA exclusion as an alternative to AC in patients with AF. 22 
ENDOCARDIAL LAA OCCLUSION DEVICES
The first device designed specifically to close the LAA mechanically was the PLAATO device (Ev3; Plymouth, Minn) that consisted of a self-expanding nitinol frame covered by an impermeable polytetrafluoroethylene membrane (Figure 1) . High-risk patients with AF who were not candidates for warfarin therapy showed an acceptable safety profile and a complete LAA occlusion rate approaching 98% with a reduction of stroke risk ranging from 42% to 65% compared with their estimated risk based on the CHADS 2 (congestive heart failure, hypertension, age ¼ 75 years, diabetes mellitus, stroke [doubled]) scoring system. [23] [24] [25] In 2007, Atritech (Plymouth, Minn) acquired the PLAATO intellectual property from Ev3, stopped production of the PLAATO, and developed the Watchman device.
The Watchman
The Watchman device (Boston Scientific, Maple Grove, Minn) is a self-expanding nitinol-based device with distal fixation barbs and a permeable polyester fabric (Figure 1 ). The Watchman was evaluated in the PROTECT-AF clinical trial that prospectively randomized (2:1) 707 patients with nonvalvular AF (CHADS 2 score 1) to receive either the Watchman device or warfarin therapy. Rates of successful Watchman implantation and complete LAA occlusion were 91% and 88%, respectively. Warfarin was also administered to the Watchman group but it was stopped when transesophageal echocardiography (TEE) documented sealing of the LAA with either no residual leak or a leak 5 mm. At 6 weeks, 86% of the Watchman group was able to stop warfarin, and 92% had stopped warfarin at 6 months. After 5 years of follow-up, the primary efficacy endpoint (decrease in stroke, systemic thromboembolism, and cardiovascular death) was 3% annually with the Watchman device and 4.3% in the warfarin group, a 99.9% probability of noninferiority of the Watchman compared with warfarin therapy. 26, 27 Despite demonstrating efficacy, the Watchman group demonstrated a significantly higher incidence of safety events. The primary safety event rate (procedural stroke, major bleeding, device embolization, and pericardial effusion) was 7.4 events per 100 patient-years in the Watchman group compared with 4.4 events per 100 patient-years in the warfarin group (relative risk, 1.69). Pericardial effusions constituted 50% of the safety events in the Watchman group (4.8%). Most safety events were early postprocedural, compared with the cumulative risk of warfarin therapy that would only increase with time. 28 Unlike the earlier PLAATO system, the Watchman has a permeable covering membrane and thus requires OAC for at least 6 weeks until complete endothelialization is confirmed by TEE, followed by dual antiplatelet therapy (DAPT) for 6 months. The ASAP study was a single-armed prospective registry addressing this concern. A total of 150 patients with a mean CHADS 2 score of 2.8 and contraindication to OAC were treated with the Watchman device and DAPT for life. The study was statistically underpowered and results were not definitive, but the numbers seemed to be lower than expected for CHADS 2 -matched individuals on only DAPT. 29 Safety events were not the only concern regarding a percutaneous approach. The number of patients screened but not included in the trial (4291 candidates excluded of 4998 screened) raised questions about the external validity of the trial. Another concern was the detection of device thrombi by TEE in 4.8% of the Watchman group. In addition, more than 30% of patients enrolled in the PROTECT-AF were found to have incomplete LAA closure at 12 months. Although disconcerting, a study of 389 of these patients concluded that residual peri-device flow was not associated with an increased risk of thromboembolism. 30 This conclusion, however, is to be interpreted with caution given the small sample size and the low event rate.
Despite the initial safety concerns, a PROTECT-AF cohort of 707 patients was followed for a mean of 45 months and the safety equilibrated while efficacy changed from noninferior to superior. 22 This is clearly because of the decreasing incidence of safety events in the Watchman group beyond the peri-procedural phase in conjunction with the incremental increase in risk over time with warfarin. The composite efficacy endpoint was also, for the first time, shown to be superior with the Watchman device (2.3 events per 100 patient-years) as compared with warfarin therapy (3.8 events per 100 patient-years) (hazard ratio 0.61, 95% confidence interval 0.38-0.97; P ¼ .035). Although ischemic strokes were still higher with the device, the more devastating hemorrhagic strokes were significantly reduced, and this was critical to the lower all-cause mortality in the device group. A more recent meta-analysis included 2406 patients from both the PROTECT-AF and subsequent PREVAIL trials and provided similar conclusions. 31 This showed LAA occlusion to result in less overall cardiovascular/unexplained mortality (1.1 vs 2.3 events/100 patient-years; hazard ratio 0.48; P ¼ .006). The overall stroke rate was not significantly different, but there were more ischemic strokes with the device and more hemorrhagic strokes with warfarin. The Food and Drug Administration (FDA) initially did not grant approval to the Watchman because of concerns regarding early safety events (procedural stroke, major bleeding, device embolization, and pericardial effusion) and lack of clear evidence of benefit. After multiple rounds of controversy and the added data from the long-term follow-up, the FDA approved the Watchman device in March 2015 for use in patients with nonvalvular AF with CHA 2 DS 2 -VASc score 2, acknowledging that the benefits associated with the Watchman may outweigh its risks, especially in patients unsuitable for or not wanting lifelong AC.
Amplatzer Cardiac Plug
The Amplatzer cardiac plug (St Jude Medical, St Paul, Minn) is a self-expanding nitinol implant consisting of a lobe and a disc connected by a central waist. The lobe is larger than that with the Amplatzer septal occluder and has 6 stabilizing wires, and the disc seals the mouth of the LAA in a ''pacifier''-like fashion (Figure 1 ). Like the early PLAATO, the Amplatzer plug does not require warfarin and, therefore, can be used in patients with contraindications to warfarin. In the early European experience, Park et al 32 retrospectively evaluated procedural safety for up to 24 hours after implantation. Their review revealed significant safety concerns for the Amplatzer plug despite the procedures being performed by highly skilled operators. The Asia-Pacific experience demonstrated a better safety profile, and at a mean follow-up of 12 months, complete LAA occlusion was accomplished in 100% of patients. 33 In terms of efficacy, Urena et al 34 implanted the Amplatzer plug in 52 patients with a mean CHADS 2 score of 3 and contraindications to OAC. Despite incomplete LAA closure in 16% of patients at 6 months, the incidence of stroke was less than expected for matched CHADS 2 scores at 20 months.
The largest experience is that of Tzikas et al 35 from their report of 1047 patients treated with the Amplatzer device. They reported a 97.3% procedural success and 4.97% procedural-related adverse events. Major adverse events included death (0.76%), stroke (0.86%), device embolization (0.77%), and major bleeding and cardiac tamponade (1.24% each). Follow-up was completed for a mean of 13 months, and the annual rates of systemic thromboembolism and major bleeding were 2.3% and 2.1%, respectively. These represented 59% and 61% risk reductions compared with the expected rates. Bleeding complications were more commonly encountered in patients resumed on aspirin compared with those on no therapy. The Amplatzer device is currently not FDA approved. A further prospective randomized (2:1) trial is now enrolling patients with previous gastrointestinal bleeding of no treatable cause and a CHA 2 DS 2 -VASc score 3 for either the Amplatzer plug or warfarin.
Additional endocardial LAA occlusion devices are in various stages of animal or early human trials. [36] [37] [38] [39] [40] EPICARDIAL LAA OCCLUSION DEVICES Epicardial LAA occlusion, although often more invasive, has several theoretical advantages: (1) avoiding a foreign body in contact with the blood stream that may be a nidus for thrombus or infection; (2) avoiding long-term, and often perioperative, anticoagulation; (3) avoiding LAA sizing and morphology concerns (except for the Lariat [SentreHEART, Palo Alto, Calif]); (4) consistent closure, with minimal residual LAA-to-left atrial leaks; and (5) lower device costs compared with the endocardial devices. Epicardial closure can be performed as an adjunct to concomitant cardiac procedures or as a stand-alone procedure. Stand-alone procedures are either surgical or percutaneous.
With Concomitant Cardiac Surgery
As previously mentioned, the ACC/AHA recommended exclusion of the LAA during surgical ablation of AF or mitral valve surgery in 2006. 19 Many techniques have been described to close the LAA with variable results. Of the previously described techniques, endocardial suturing is perhaps the worst because there is a residual LAA-to-left atrial connection in more than half of the patients. Surgical excision of the LAA followed by a double-layered suture closure of the left atrial wall defect is superior to any other technique in terms of efficacy but requires the patient to be on cardiopulmonary bypass, preferably under cardioplegic arrest to prevent air embolism. External LAA closure using a stapling device is an effective way to close the LAA but leaves a residual ''pouch'' of greater than 1 cm at the base of the LAA in more than one-third of patients, and these pouches are thrombogenic. 18, 41 The stapler technique has the advantage of being suitable for off-pump or less-invasive heart surgery. Variation in epicardial clamps and energy devices have been described, and uniformly had a higher and a more consistent complete closure than endocardial sutures. [42] [43] [44] As mentioned, the Watchman device demonstrated that LAA closure can potentially replace OAC. Confirmation of this message in a surgical population is being evaluated in the LAAOS III study. 45 This study is randomizing 4700 patients with AF undergoing on-pump procedures for ligation or nonligation of the LAA and is expected to be completed in 2016. Two devices with nearly a 100% complete occlusion rate have been designed for LAA closure with concomitant cardiac procedures. The TigerPaw II (Maquet Cardiovascular LLC, Wayne, NJ). This device consists of a fastener and a disposable delivery tool. The fastener is composed of linearly spaced connectors covered with soft silicone (Figure 2) . The spacing allows it to conform to the anatomy of the LAA.
One clinical trial has been conducted and included 60 patients undergoing open cardiac surgery. 46 One patient required repair of a tear site related to manual manipulation after fastener application. At 90 days, a complete occlusion rate of 100% was demonstrated in the 54 patients available for follow-up. The system was approved by the FDA for use with concomitant open cardiac procedures, but thus far, no stand-alone LAA closures using this device have been reported. Recently, the FDA issued a class I recall for the TigerPaw device due to increased safety concerns associated with bleeding and appendage tears. The AtriClip (Atricure Inc, Westchester, Ohio). First, second, and third generations of this device were used in early animal studies in which no complications were reported and the occlusion rates at 90 days were consistently 100%. [47] [48] [49] [50] The AtriClip is made of 2 parallel straight titanium tubes with elastic nitinol springs covered by knit braided polyester to enhance fibrosis (Figure 2 ). The nitinol springs provide continuous dynamic pressure on each of the titanium tubes to enhance permanent closure of the LAA. The Atriclip can be used on a beating heart and the design allows redeployment in case of initial suboptimal placement. The device has been studied and approved for LAAE closure with concomitant cardiac procedures both in Europe and the United States. In 2009, the device achieved the CE mark after Salzberg et al 51 demonstrated feasibility and safety on 34 patients undergoing cardiac surgery. These authors demonstrated safety with no devicerelated complications, and intraoperative TEE confirmed complete occlusion in 100% of the cases. Short-term efficacy was demonstrated after 3 months, confirming complete occlusion and Atriclip stability by computed tomography (CT) in all patients.
In the United States, FDA approval of the AtriClip followed the EXCLUDE trial that enrolled 71 patients with CHADS 2 score >2 undergoing open cardiac procedures in 7 US centers. In 1 patient, the LAA morphology was not suitable for clip application. The rate of complete exclusion was 95.7% by intraoperative TEE. After 3 months, there were no adverse events, and complete occlusion was confirmed by CT scan and TEE in 98.4% of the cases. 52 Stand-alone LAA closure using the AtriClip also has been reported and currently a study for thoracoscopic AtriClip application completed recruiting patients with CHADS 2 score 2 and contraindication for OAC. The results are expected to provide a clearer understanding of the role of the AtriClip device in patients not undergoing cardiac surgery.
Stand-Alone Epicardial LAA Occlusion Surgical epicardial LAA occlusion. The thoracoscopic approach to LAA occlusion was first reported by Blackshear et al 53 using loop snares or a stapling device in 15 patients with failed or contraindicated warfarin therapy, most of whom had suffered previous thromboembolic events. The procedure appeared safe and there was a statistical trend toward thromboembolic risk reduction. In a more recent study, Ohtsuka et al 54 performed 30 stand-alone thoracoscopic LAA excisions using an endoscopic cutter. They included 21 patients with a mean CHA 2 DS 2 -VASc score of 4.5 and contraindications to warfarin. Feasibility and safety results were acceptable with a mean operative time of only 32 minutes, although 2 patients required minithoracotomies for dense pleura-pericardial adhesions. No major complications were encountered. At 3 months, complete LAA occlusion was confirmed by CT scan in 100% of patients. All OAC was discontinued and at 16 months no strokes or thromboembolic events were reported.
Devices for LAA epicardial LAA occlusion also have been developed. The earliest was the Cardioblate (Medtronic Inc, Minneapolis, Minn). The device was an expandable silicone band marked with radio-opaque clips. Animal studies reported successful thoracoscopic implantation with no complications and a 100% complete occlusion rate. 55 Unfortunately, further stand-alone human implantation was not attempted after a study that was intended to enroll 60 patients undergoing an open cardiac procedure was discontinued after the first 40 patients because of high rates of residual communications between the left atrium and LAA.
The other device designed for surgical epicardial LAA closure is the AtriClip (Atricure Inc). The AtriClip seems to be more promising, and as previously mentioned, a feasibility study for thoracoscopic AtriClip application was initiated with excellent outcomes. Current plans exist for a larger pivotal trial based on FDA recommendations. Several other devices also have been developed for the same purpose, but are still in the developmental stage. Percutaneous epicardial LAA occlusion. This involves the Lariat (SentreHEART). This system uses a unique technique that combines endocardial and epicardial approaches. The system is based on a percutaneous transseptal delivery of a magnet-tipped endocardial catheter that approximates transmurally to another epicardial magnet-tipped guidewire that is inserted via the pericardium. A previously tied radio-opaque suture is guided down the wire and tightened at the base of the LAA (Figure 2) . The FDA approved the device on a 510K after the demonstration of satisfactory results in 2 animal studies. 56, 57 The European experience with the Lariat was reported by Bartus et al 58, 59 in 2 consecutive studies. In the PLACE II study, 89 patients who were poor candidates for OAC and with a low risk for AF underwent closure of the LAA with a Lariat device. Three patients were excluded from the study due to pericardial adhesions. The authors reported a 96% procedural success after 1 case could not be completed because of pericardial adhesions, 1 case in which the transseptal puncture could not be performed, and 2 cases in which there were pericardial access complications. Patients with superior-posterior LAA orientation also were excluded from the study. Significant adverse events included 2 cardiac tamponades requiring drainage due to right ventricular (RV) puncture. Two patients experienced postprocedural pericarditis, one of which triggered a diagnostic coronary angiography. One patient had a late pericardial effusion. At 1 year, complete LAA closure was confirmed in 98% of patients, but 1 patient was found to have a thrombus in the left atrium. The efficacy of the Lariat itself for stroke prevention was difficult to determine because 55% of the patients were continued on warfarin.
The US experience with the Lariat device was reported by Massumi et al 60 and Stone et al. 61 The former study included 20 patients with a mean CHADS 2 score of 3.2, including 15 patients with contraindications to OAC. They reported a procedural success of 100% and complete closure rate of 95%. One patient had perforation of the RV that required open surgical repair and another patient experienced cardiac tamponade due to pericardial effusion requiring drainage. Three more patients presented shortly after the procedure with severe pericarditis requiring hospitalization, with 1 requiring drainage. At 3 months' follow-up, only 1 patient had persistent Doppler flow between the LA and the LAA. At a mean follow-up of 11.7 months, no strokes or thromboembolic events were reported. Stone et al 61 studied 27 patients with contraindications to OAC and a mean CHADS 2 score of 3.5. Procedural success and completeness of LAA occlusion were 93% and 96%, respectively. One patient experienced an LAA perforation requiring drainage and blood transfusion and eventually underwent a Maze procedure with LAA ligation FIGURE 3. Proposed approach to stroke risk reduction in patients with atrial fibrillation not undergoing open cardiac procedures. *Preferred, with contraindications to anticoagulation or unfavorable left atrial appendage morphology. **Preferred with nonsurgical candidates and those with previous cardiac or left thoracic surgery. CHA 2 DS 2 -VASc, congestive heart failure, hypertension, age >75 and diabetes mellitus, previous history of stroke or transient ischemic attack, vascular disease, age 65-74 years, and female sex category; AC, anticoagulation, TTR, time in therapeutic range, LAA, left atrial appendage; LAAE, left atrial appendage exclusion. the following day. Another patient suffered a procedural stroke related to thrombus from the transseptal sheath, and 3 patients had postprocedural pericarditis. At 1 month follow-up, 1 patient suffered a stroke believed to be aortic in origin. Forty-five days after the procedure, 100% occlusion of the LAA was confirmed.
At least 3 cases have been reported with left atrial and/or LAA thrombus formation after Lariat application. [57] [58] [59] Relatively high rates of RV and LAA punctures and perforations often requiring drainage as well as procedure-related pericarditis/effusion are at many times of clinical consequences. For now, the FDA recently issued a safety communication regarding the Lariat: 45 adverse events were reported, 75% of which required emergent surgery and resulted in 6 mortalities. 62 Meanwhile, Sentre-HEART reports that more than 3700 Lariat procedures have been performed in the United States since 2009 with a very good safety profile. More prospective data are needed.
CONCLUSIONS
Warfarin predisposes to bleeding, it is difficult in many patients to stabilize the dosage to keep the patients in the therapeutic range, and patient compliance is a problem with up to 50% of all patients discontinuing warfarin within 24 months of its initiation. 63 In addition, warfarin therapy requires frequent blood tests throughout its therapy. This leaves patients with AF in search for a safer, more reliable, and more convenient alternative that is at least as good as warfarin. Newer ACs seem to provide some clinical benefits, including the lack of frequent blood test requirements. Unfortunately, even with NOACs, there is a substantial risk of bleeding, they often replace a once-daily warfarin dose with a twice-daily dose, and after 2 years of initiation, almost 25% of all patients discontinued them.
As a result of these problems with OAC, the interest in mechanical LAA closure is increasing. A quality-of-life survey on a subset of 547 patients in the PROTECT-AF trial showed that patients who underwent LAA closure and were off warfarin were generally happier than those on warfarin. 64 A major benefit of the PROTECT-AF trial is that for the first time the concept for mechanical LAA closure was proven. It is the first adequately powered RCT to prove the long-argued theory that LAA exclusion offers protection from stroke associated with AF. Although very promising, some unresolved issues exist. 65 The efficacy of the Watchman device in patients who can tolerate neither initial AC nor DAPT is not known. Similarly, longer-term efficacy is yet to be better demonstrated and understood. Another potential concern exists as some patients with AF may have other noncardiac etiologies for ischemic strokes, which may be better addressed by AC than by LAAE. These concerns are valid, and the magnitude of which will be better understood over the following years. While we await more data about existing and upcoming LAA occlusion devices, our proposed strategy may be a viable option in selected patients as an alternative to OAC (Figures 3 and 4) . We recommend reliable surgical epicardial LAA exclusion in all patients with AF undergoing open cardiac surgery or thoracoscopic ablation. We also recommend isolated procedures for surgical epicardial LAA exclusion in patients with AF failing AC or those with absolute contraindications to AC, making them unable to tolerate the initial recommended AC period with an effective percutaneous technique. We make the same recommendation for patients with AF not preferring AC but who have an LAA morphology that is not favorable for percutaneous devices.
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